Navigation Links
BIO Ventures for Global Health Announces Management Changes
Date:6/25/2009

Christopher D. Earl Resigning as CEO

Board member Melinda Moree named interim leader

WASHINGTON, June 25 /PRNewswire-USNewswire/ -- BIO Ventures for Global Health (BVGH) today announced that Christopher D. Earl, Ph.D., will resign from BVGH, effective July 9, 2009. Melinda Moree, Ph.D., a member of the board since BVGH's inception, will serve as interim CEO until a permanent replacement is hired.

"I've been galvanized by my experience in global health and honored to have the opportunity to contribute," says Dr. Earl. "I look forward to continuing to work at the interface of public health, science, and entrepreneurship."

"Chris's imagination and expertise have enabled BVGH to demonstrate the integral role the biotechnology industry can play in addressing the urgent medical needs of developing countries," says Robert B. Chess, Chairman of BVGH. "From promoting new financial incentives that reward companies for investing in global health R&D, to creating Innovation Maps that define a path toward making new breakthrough therapies, we thank Chris for his commitment and contributions. In particular, we are pleased that BVGH secured a three-year, $7 million renewal of funding from the Bill & Melinda Gates Foundation under Chris' leadership."

Melinda Moree, Ph.D., previously served as Executive Director for the PATH Malaria Vaccine Initiative, a $50 million/year Product Development Partnership funded by the Bill & Melinda Gates Foundation. She also served as Vice President, Global Health Services, Applied Strategies, supporting global, regional, and national health organizations in their mission to improve human health worldwide.

"BVGH has had an impact through initiatives launched by Chris such as last year's Partnering for Global Health Forum that brought together biotechnology executives and global health innovators," says Jim Greenwood, President and CEO of the Biotechnology Industry Organization and a member of the BVGH Board. "We look forward to continued success through Melinda's knowledge of BVGH and depth of experience in forging partnerships between the private and public sectors to keep BVGH operating at a high level."

About BIO Ventures for Global Health

BIO Ventures for Global Health (BVGH), a non-profit organization, is harnessing the resources of the biotechnology industry to create new medicines for infectious diseases of the developing world. BVGH breaks down barriers that hinder industry initiatives in global health product development. We foster collaboration among stakeholders in industry, philanthropy, academia, and government, and we catalyze industry investment through the creation of new market-based incentives. For more information please visit www.bvgh.org.


'/>"/>
SOURCE BIO Ventures for Global Health
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hank Plain Joins Morgenthaler Ventures as Partner
2. Dan Broderick Joins Prolog Ventures as Partner
3. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. Khosla Ventures and BIOeCON Form KiOR Inc.
6. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
7. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
8. Clarus Ventures Closes $660 Million Fund
9. The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C.
10. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
11. SPO Medical Retains American Capital Ventures for Investor Relations Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):